MA34158B1 - Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée - Google Patents

Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée

Info

Publication number
MA34158B1
MA34158B1 MA35308A MA35308A MA34158B1 MA 34158 B1 MA34158 B1 MA 34158B1 MA 35308 A MA35308 A MA 35308A MA 35308 A MA35308 A MA 35308A MA 34158 B1 MA34158 B1 MA 34158B1
Authority
MA
Morocco
Prior art keywords
dihydroimidazo
component
quinazoline
combinations
solvate
Prior art date
Application number
MA35308A
Other languages
English (en)
Inventor
Ningshu Liu
Andrea Haegebarth
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44144895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34158(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA34158B1 publication Critical patent/MA34158B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne : * des combinaisons de : composant A : un ou plusieurs composés de 2,3-dihydroimidazo[1,2-c]quinazoline de formule générale (A1) ou (A2), ou un sel, solvate, hydrate ou stéréoisomère physiologiquement acceptable de celui-ci; composant B : un ou plusieurs composés de N-(2-arylamino)arylsulfonamide de formule générale (B), ou lapatinib, ou paclitaxel, ou un sel, solvate, hydrate ou stéréoisomère physiologiquement acceptable de celui-ci; et, facultativement, composant C : un ou plusieurs autres agents pharmaceutiques; où facultativement certains ou tous les composants sont sous la forme d'une formulation pharmaceutique qui est prête pour utilisation pour être administrés simultanément, conjointement, séparément ou séquentiellement, dépendamment les uns des autres, par voie orale, intraveineuse, topique, locale, par instillation, intrapéritonéale ou nasale; * l'utilisation de telles combinaisons pour la préparation d'un médicament pour le traitement ou la prophylaxie d'un cancer; et * un kit comprenant une telle combinaison.
MA35308A 2010-04-16 2011-04-14 Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée MA34158B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10160109 2010-04-16
PCT/EP2011/055917 WO2011128407A2 (fr) 2010-04-16 2011-04-14 Combinaisons contenant une 2,3-dihydroimidazo[1,2-c]quinazoline substituée

Publications (1)

Publication Number Publication Date
MA34158B1 true MA34158B1 (fr) 2013-04-03

Family

ID=44144895

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35308A MA34158B1 (fr) 2010-04-16 2011-04-14 Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée

Country Status (24)

Country Link
US (1) US20130184270A1 (fr)
EP (1) EP2558126A2 (fr)
JP (1) JP5886271B2 (fr)
KR (1) KR20130098155A (fr)
CN (1) CN102958540B (fr)
AU (1) AU2011240003A1 (fr)
BR (1) BR112012026480A2 (fr)
CA (1) CA2796253A1 (fr)
CL (1) CL2012002887A1 (fr)
CO (1) CO6620036A2 (fr)
CR (1) CR20120524A (fr)
CU (1) CU20120150A7 (fr)
DO (1) DOP2012000269A (fr)
EA (1) EA201201414A8 (fr)
EC (1) ECSP12012261A (fr)
HK (1) HK1182937A1 (fr)
IL (1) IL222356A0 (fr)
MA (1) MA34158B1 (fr)
MX (1) MX2012012064A (fr)
PE (1) PE20130191A1 (fr)
SG (1) SG184550A1 (fr)
TN (1) TN2012000493A1 (fr)
WO (1) WO2011128407A2 (fr)
ZA (1) ZA201208616B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (fr) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement du myélome
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (fr) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés
WO2014160034A1 (fr) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Modulateurs d'aldéhyde déshydrogénase-1 et leurs procédés d'utilisation
SG11201507265XA (en) 2013-04-08 2015-10-29 Bayer Pharma Aktiengesllschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
WO2015082376A2 (fr) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Utilisation d'inhibiteurs de pi3k
MX2017011635A (es) * 2015-03-09 2018-02-09 Bayer Pharma AG Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida.
EP3268005A1 (fr) * 2015-03-09 2018-01-17 Bayer Pharma Aktiengesellschaft Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées
WO2017153220A1 (fr) * 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-méthoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
EP3723754A4 (fr) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. Composés imidazo[1,2-c]quinazolin-5-amine présentant des propriétés antagonistes du a2a

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ES2367141T3 (es) * 2002-09-30 2011-10-28 Bayer Pharma Aktiengesellschaft Derivados de azol-pirimidina condensados.
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
DE102004037875B4 (de) 2004-08-04 2008-05-08 Siemens Ag Sensorvorrichtung, Verfahren und Vorrichtung zum Überwachen einer Sensorvorrichtung
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
PL1912636T3 (pl) * 2005-07-21 2015-02-27 Ardea Biosciences Inc N-(aryloamino)sulfonamidowe inhibitory mek
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
SG189784A1 (en) * 2008-04-14 2013-05-31 Ardea Biosciences Inc Compositions and methods for preparing and using same
EP2168583A1 (fr) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement du myélome

Also Published As

Publication number Publication date
CU20120150A7 (es) 2013-02-26
CN102958540B (zh) 2015-09-02
JP5886271B2 (ja) 2016-03-16
US20130184270A1 (en) 2013-07-18
CA2796253A1 (fr) 2011-10-20
WO2011128407A3 (fr) 2012-02-23
CN102958540A (zh) 2013-03-06
MX2012012064A (es) 2012-12-17
WO2011128407A9 (fr) 2011-12-22
ZA201208616B (en) 2015-08-26
IL222356A0 (en) 2012-12-31
DOP2012000269A (es) 2012-12-15
AU2011240003A1 (en) 2012-11-08
CR20120524A (es) 2013-01-09
KR20130098155A (ko) 2013-09-04
EA201201414A8 (ru) 2013-12-30
BR112012026480A2 (pt) 2016-08-16
WO2011128407A2 (fr) 2011-10-20
CO6620036A2 (es) 2013-02-15
HK1182937A1 (en) 2013-12-13
TN2012000493A1 (en) 2014-04-01
CL2012002887A1 (es) 2013-01-18
SG184550A1 (en) 2012-11-29
ECSP12012261A (es) 2012-11-30
PE20130191A1 (es) 2013-02-21
JP2013525293A (ja) 2013-06-20
EP2558126A2 (fr) 2013-02-20
EA201201414A1 (ru) 2013-04-30

Similar Documents

Publication Publication Date Title
MA34158B1 (fr) Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée
MA34553B1 (fr) Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
ES2928408T3 (es) Métodos para el tratamiento de enfermedades fibróticas
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA34083B1 (fr) Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
JP6456383B2 (ja) イソチオシアネート系化合物と抗癌薬の併用
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
BRPI0611705A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
EA200601724A1 (ru) Новые композиции для местной доставки
BRPI0511967B8 (pt) derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina, seu uso e composição farmacêutica que os compreende
MY143795A (en) Tetrahydropyridoindole derivatives
JP2002520273A (ja) 抗うつ効果を有する治療薬
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
MA44206B1 (fr) Comprimé orodispersible comprenant estetrol
MA28429B1 (fr) Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases
US8906951B1 (en) Use of NK-1 receptor antagonists in pruritus
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
ZA200602433B (en) Therapeutic treatment
MA45043A (fr) Composés pour stimuler la croissance des cheveux et/ou inhiber ou retarder la chute des cheveux chez l'homme, et compositions pour de telles utilisations
MA46342B1 (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
BRPI0716214A2 (pt) Composições farmacêuticas para o tratamento de infecções fúngicas.